Cover Story
Capitol HillFree
By Matthew Bin Han Ong
After taking eight months to respond to a House committee’s questions about policies on handling of sexual misconduct cases, a letter from NIH has provided answers that critics describe as vague and inadequate.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Trump 2016: A look back at the 45th president’s impact on oncology